Compare PHAR & TNDM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PHAR | TNDM |
|---|---|---|
| Founded | 1988 | 2006 |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | 2020 | 2013 |
| Metric | PHAR | TNDM |
|---|---|---|
| Price | $12.94 | $18.54 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 19 |
| Target Price | ★ $38.33 | $28.00 |
| AVG Volume (30 Days) | 4.5K | ★ 1.5M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,014,736,000.00 |
| Revenue This Year | $10.04 | $8.11 |
| Revenue Next Year | $2.51 | $11.85 |
| P/E Ratio | $3,041.22 | ★ N/A |
| Revenue Growth | N/A | ★ 7.93 |
| 52 Week Low | $10.55 | $10.00 |
| 52 Week High | $21.34 | $29.65 |
| Indicator | PHAR | TNDM |
|---|---|---|
| Relative Strength Index (RSI) | 38.08 | 61.29 |
| Support Level | $11.88 | $17.79 |
| Resistance Level | $13.61 | $18.23 |
| Average True Range (ATR) | 0.46 | 1.01 |
| MACD | -0.11 | 0.21 |
| Stochastic Oscillator | 3.92 | 93.31 |
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.